Robert Kammer - Imprimis Pharmaceuticals Chairman of the Board
Chairman
Dr. Robert J. Kammer, D.D.S., is Chairman of the Board of Imprimis Pharmaceuticals, Inc., since April 1, 2012. Dr. Kammer is a founder of our Company and has served as our director since December 2011 and as Chairman of the Board since April 2012. In June 2014, Dr. Kammer joined the board of directors of SoftScience Shoe Company as the cochairman. In January 2015, Dr. Kammer retired from his clinical practice as a dentist, in which he was engaged from 1975 to 2015. He is a retired Diplomate of The American Board of Orofacial Pain and a Founding Member of The Academy for Sports Dentistry and Colorado Osseointegration Study Club. From 1979 to 1996, Dr. Kammer was an Associate Professor at the University of Colorado School of Dental Medicine. Dr. Kammer has also served as a consultant to the BoulderDenver Pain Control Center and a reviewer for the Journal of Orofacial Pain. Dr. Kammer recently contributed a chapter to the text Osteoperiosteal Flap, has coauthored multiple scientific articles, was coinvestigator on a Dental Implant Bar Study at the Mayo Institute from 2011 to 2013 and served as a consultant for Clear Choice Dental Implant Centers from 2010 to 2013 since 2012.
| Age | 63 |
| Tenure | 12 years |
| Professional Marks | Ph.D |
| Phone | 858-704-4040 |
| Web | http://www.imprimisrx.com |
Imprimis Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (11.94) % which means that it has lost $11.94 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (153.09) %, meaning that it created substantial loss on money invested by shareholders. Imprimis Pharmaceuticals' management efficiency ratios could be used to measure how well Imprimis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 15.28 M in liabilities with Debt to Equity (D/E) ratio of 343.1, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Imprimis Pharmaceuticals has a current ratio of 1.11, suggesting that it may not be capable to disburse its financial obligations when due. Debt can assist Imprimis Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Imprimis Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Imprimis Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Imprimis to invest in growth at high rates of return. When we think about Imprimis Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 10 records | CHAIRMAN Age | ||
| Nathaniel Taylor | National Vision Holdings | 41 | |
| Walter DAlessio | Brandywine Realty Trust | 81 | |
| Michael Joyce | Brandywine Realty Trust | 79 | |
| Timothy Mason | National Vision Holdings | 57 | |
| Robert Gamgort | Keurig Dr Pepper | 62 | |
| John Kite | Kite Realty Group | 58 | |
| William Currie | National Vision Holdings | 52 | |
| Robert Willett | National Vision Holdings | 68 | |
| Anthony Nichols | Brandywine Realty Trust | 78 | |
| Gerard Sweeney | Brandywine Realty Trust | 67 | |
Management Performance
| Return On Equity | -153.09 | |||
| Return On Asset | -11.94 |
Imprimis Pharmaceuticals Leadership Team
Elected by the shareholders, the Imprimis Pharmaceuticals' board of directors comprises two types of representatives: Imprimis Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Imprimis. The board's role is to monitor Imprimis Pharmaceuticals' management team and ensure that shareholders' interests are well served. Imprimis Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Imprimis Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Nelson, Director | ||
| Robert Kammer, Chairman of the Board | ||
| Clayton Edwards, COO | ||
| John Saharek, Chief Commercial Officer | ||
| Anthony Principi, Independent Director | ||
| Andrew Boll, Vice President - Accounting and Financial Reporting | ||
| Mark Baum, CEO, Director | ||
| Richard Lindstrom, Director | ||
| Stephen Austin, Independent Director |
Imprimis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Imprimis Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -153.09 | |||
| Return On Asset | -11.94 | |||
| Profit Margin | (16.81) % | |||
| Operating Margin | (13.94) % | |||
| Current Valuation | 120.54 M | |||
| Shares Outstanding | 23.28 M | |||
| Shares Owned By Insiders | 7.16 % | |||
| Shares Owned By Institutions | 23.26 % | |||
| Number Of Shares Shorted | 231.01 K | |||
| Price To Earning | (2.02) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Other Consideration for investing in Imprimis Stock
If you are still planning to invest in Imprimis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Imprimis Pharmaceuticals' history and understand the potential risks before investing.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |